FDA Approved: BRIXADI — Supplemental Application (Braeburn Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BRIXADI (buprenorphine) from Braeburn Inc., resulting in updated labeling and/or expanded indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• BRIXADI (Buprenorphine)

Snippet

SUPPL AP for BRIXADI (BUPRENORPHINE)